基石药业（苏州）有限公司招聘

CStone Pharmaceuticals is an innovative, research-driven biopharmaceutical enterprise dedicated to pioneering the development of cutting-edge therapeutic medications. Situated in both Shanghai and Suzhou, the company boasts a leadership team comprised of experienced executives from leading multinational pharmaceutical corporations. In July 2016, CStone disclosed the successful conclusion of its Series A funding round, securing a total investment of $150 million (approximately 975 million RMB). This round was co-invested by three prominent industry investors: Oriza Seed Venture Capital (Oriza Seed), Boyu Capital, and WuXi Healthcare Ventures (WXHV).

With an unwavering commitment to addressing the critical healthcare needs of Chinese patients, CStone's extensive pipeline encompasses five therapeutic areas: oncology, cardiovascular diseases, rheumatoid arthritis, hematology, and autoimmune disorders. The company's strategic focus on immuno-oncology serves as its cornerstone, aiming to propel Chinese research onto the global stage through its world-class research and development capabilities, an innovative drug portfolio, and an open innovation approach.

CStone Pharmaceuticals is a pioneering, research-focused biopharmaceutical company headquartered in Shanghai and Suzhou, China. Its executive team comprises seasoned professionals from top-tier multinational pharmaceutical firms. In July 2016, the company successfully concluded its Series A funding round, attracting a total investment of $150 million (equivalent to approximately 975 million RMB). This round was jointly supported by three distinguished industry investors: Oriza Seed Venture Capital (Oriza Seed), Boyu Capital, and WuXi Healthcare Ventures (WXHV).

Driven by a mission to meet the pressing medical needs of Chinese patients, CStone's comprehensive product pipeline spans across five therapeutic sectors: oncology, cardiovascular diseases, rheumatoid arthritis, hematology, and autoimmune diseases. With immuno-oncology at the heart of its strategic focus, the company aspires to position Chinese research on the global stage, leveraging its world-class research and development expertise, innovative drug portfolio, and an open innovation philosophy.